Selective, brain penetrant 5-HT(1B/D) receptor agonist

Novel dual-targeted inhibitor of sphingosine kinase and microtubule polymerization

Potent inhibitor of Dengue viruses (DENV), displaying activities against all four serotypes of DENV, as well as to a related flavivirus, West Nile virus (WNV), and an alphavirus, Sindbis virus (SINV)

Potent influenza A virus (IAV) entry inhibitor, targeting a conserved region of hemagglutinin

Novel inhibitor of NF

Millepachine analog, inhibiting tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin

Biological Active Reagents

Potent anticancer agent, downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK

Novel multikinase inhibitor, potently inhibiting angiogenesis-related kinases including VEGFR1/2/3, and FGFR2, and the Src kinase

Novel FLT3 and Wnt/β-catenin signaling inhibitor, displaying potent activity in models of FLT3-driven AML

Novel inhibitor of cell-cycle progression, inducing G0/G1 phase arrest and apoptosis in human hepatic carcinoma cells

Novel inhibitor of OLIG2 in glioblastoma

Specific Inhibitor of Skp2-Mediated p27 Degradation

Specific Inhibitor of Skp2-Mediated p27 Degradation

First-in-class Specific Inhibitor of Skp2-Mediated p27 Degradation

Novel microtubule-destabilizing agent, exerting potent antitumor activity against esophageal squamous cell carcinoma

Novel microtubule-destabilizing agent, exerting potent antitumor activity against esophageal squamous cell carcinoma

Full agonist of GABAA receptors containing α2 and α3 subunits, and partial agonist of α1 and α5 subunits.

Novel nonpeptide AT1 receptor antagonist, acting as a modulator on RAAS and KKS activation during COVID-19

Potential synthetic lethal lead, targeting E-cadherin-deficient cells

Novel Potent Dual inhibitor of SLK (STE20-like kinase) and STK10 (serine/threonine kinase 10)

Novel highly selective and potent κ opioid agonist (κ, Ki = 0.47 nM, κ/μ = 682, κ/δ = 283)